

GLAXOSMITHKLINE PLC
Form 6-K
April 19, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 19 April 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
 - b) Nature of the transaction
 - c) Price(s) and volume(s) Price(s) Volume(s)
£16.39 575.028
 - d) Aggregated information n/a (single transaction)
- Aggregated volume Price

e) Date of the transaction 2017-04-13
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor
 b) Position/status President, Global Manufacturing & Supply
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on Ordinary Shares held in the Company's Deferred Investment Award Programme.

b) Nature of the transaction

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.39 230.011
 n/a (single transaction)

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2017-04-13
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain
 b) Position/status President, Global Pharmaceuticals
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - ISIN: GB0009252882
 - Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
 - b) Nature of the transaction
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.39	287.514
n/a (single transaction)	
 - d) Aggregated information
 - Aggregated volume Price
 - e) Date of the transaction 2017-04-13
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr B McNamara
 - b) Position/status CEO, GSK Consumer Healthcare
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053
 Increase in notional interest
 in ADSs following the
 re-investment of dividends
 paid to shareholders on 13
 April 2017 on ADSs held in
 the Company's Deferred
 Investment Award
 Programme.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
\$41.8150	359.648
n/a (single transaction)	

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction

2017-04-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr D S Redfern

b) Position/status

Chief Strategy Officer

c) Initial notification/
 amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

a) Description of the financial instrument

Ordinary shares of 25 pence
 each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest
 in Ordinary Shares following
 the re-investment of
 dividends paid to
 shareholders on 13 April
 2017 on Ordinary Shares held
 in the Company's Deferred
 Investment Award
 Programme.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.39	230.011

n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status Senior Vice President, HR

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.39 230.011
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, R&D
- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £16.39 | 287.514 |
| n/a (single transaction) | |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-04-13
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 19, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc